Phase I dose‑escalation study on irinotecan, cisplatin, and S‑1 combination in chemotherapy‑naïve patients with HER2‑negative advanced gastric cancer (HERBIS‑4B, OGSG 1106)
論文
Effect of the number of cycles of docetaxel + S‑1 therapy on long‑term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials
TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer
Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease
Neoadjuvant docetaxel, oxaliplatin and S‑1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902) protocol of a multi‑center, phase II study
The Phase II Study of Panitumumab in Chemotherapy- Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer OGSG 1602 Final Results
Protocol of OGSG 1901 a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy
Sequential Treatment Strategy Using Fluoropyrimidine plus Bevacizumab Followed by Oxaliplatin for Metastatic Colorectal Cancer A Phase II Study (OGSG 1107)
Three-year outcomes of a phase Ⅱ study of adjuvant chemotherapy with S-1 plus docetaxel for stage Ⅲ gastric cancer after curative D2 gastrectomy
Randomized, Open-Label Phase II Study Comparing Capecitabine- Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial